Fresenius entered an agreement with Worldwide Hospital Group (WWH) to fully divest Vamed’s international project business (Health Tech Engineering, HTE). In May 2024, Fresenius originally announced a gradual wind-down of the HTE project business, largely to be completed by 2026, as part of Fresenius’ structured exit from its Investment Company Vamed. The divestment will now accelerate the exit and enable Fresenius to further increase focus and management capacity on the ongoing progress of its core businesses Fresenius Kabi and Fresenius Helios, in line with #FutureFresenius. For the employees of Vamed’s international project business, the transaction offers the perspective of the continuation of the business.
Worldwide Hospitals Group (WWH), a healthcare company based in Germany, specializes in delivering flexible modular hospital solutions—both at sea and on land. Vamed's international project business will complement and enhance WWH's core business.
Closing is expected mid of 2025 and subject to the fulfilment of certain closing conditions.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release
Fresenius entered an agreement with Worldwide Hospital Group (WWH) to fully divest Vamed’s international project business (Health Tech Engineering, HTE). In May 2024, Fresenius originally announced a gradual wind-down of the HTE project business, largely to be completed by 2026, as part of Fresenius’ structured exit from its Investment Company Vamed. The divestment will now accelerate the exit and enable Fresenius to further increase focus and management capacity on the ongoing progress of its core businesses Fresenius Kabi and Fresenius Helios, in line with #FutureFresenius. For the employees of Vamed’s international project business, the transaction offers the perspective of the continuation of the business.
Worldwide Hospitals Group (WWH), a healthcare company based in Germany, specializes in delivering flexible modular hospital solutions—both at sea and on land. Vamed's international project business will complement and enhance WWH's core business.
Closing is expected mid of 2025 and subject to the fulfilment of certain closing conditions.
Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE) is a global healthcare company headquartered in Bad Homburg v. d. Höhe, Germany. In the 2023 fiscal year, Fresenius generated €22.3 billion in annual revenue. Fresenius offers solutions to the social challenges posed by a growing and ageing population and the resulting need for affordable, high-quality healthcare. Fresenius currently counts over 175,000 employees. The Fresenius Group comprises the operating companies Fresenius Kabi and Fresenius Helios as well as the investment company Fresenius Medical Care. With 140 hospitals and countless outpatient facilities, Fresenius Helios is the leading private hospital operator in Germany and Spain, treating around 26 million patients every year. Fresenius Kabi’s product portfolio includes a range of highly complex biopharmaceuticals, clinical nutrition, medical technology, and generic intravenous drugs. Fresenius was established in 1912 by the Frankfurt pharmacist Dr. Eduard Fresenius. After his death, Else Kröner took over management of the company in 1952. She laid the foundations for a global enterprise that today pursues the goal of improving people’s health. The largest shareholder is the non-profit Else Kröner-Fresenius Foundation, which is dedicated to advancing medical research and supporting humanitarian projects.
Sustainability is a dynamic field, with new issues constantly emerging and regulatory requirements increasing. For us, however, sustainable activity means more than merely complying with regulations. It is a key aspect of our corporate promise: We are “Committed to Life.”
What exactly is behind our commitment to sustainability?
Sarah Tix: As a healthcare company, it goes without saying that we take care of people – it is part of our DNA. Ever since our company was founded over 100 years ago, there has always been an ethical element to the high quality of our products and therapies – after all, the health of millions of people depends on it.
In concrete terms, our commitment means that we give the subject of sustainability a structure within which we define goals and metrics. That is how we firmly embed them in the entire business, taking two major aspects into consideration: people and planet. The people are our employees, patients, and other stakeholders. When it comes to the planet, we are talking about the environment and climate action.
What exactly does this mean for people and planet?
Sarah Tix: We want to offer our patients high-quality treatments and products. This means achieving above-average results in treatments and delivering markedly better product quality, which simply isn’t possible without our employees. That is why we want to create optimal working conditions for them. Moreover, it is about integrity and doing what is morally right. By this we mean complying with legal requirements and rules, but also taking a stance on social and entirely fundamental issues, such as human rights.
A healthy planet is a key prerequisite for health. That is why climate action is an important part of our activities. The healthcare industry accounts for about five percent of global carbon emissions. As such, our aim is to continuously reduce the carbon footprint along the entire value chain and thus achieve net zero by 2050. In our own line of business, we want to halve our so-called Scope 1 and Scope 2 emissions by 2030 and be a climate-neutral company by 2040.
The subject of sustainability has long been considered the key issue of the future, but there is also currently a great deal of controversy surrounding it. Is the subject still relevant?
Sarah Tix: Yes, absolutely. In our view, sustainability management represents a real opportunity and is essential for securing the resilience, competitiveness, and long-term success of companies. Far from being a short-term trend, sustainability leads to better patient care and contributes to a stable market position in the long term.
-
Hospital operations rely on many products that are procured by the purchasing department. -
![]()
The production of medicines is dependent on the purchase of chemical precursors.
What are the focus areas for 2025?
Sarah Tix: This year, we will continue to drive our sustainability ambition while working on its operationalization and transparency aspects. For instance, we will firm up our climate transition plan. We want to further reduce our energy consumption and increase the use of renewable energy in order to achieve our reduction targets for Scope 1 and Scope 2 emissions.
Our Scope 3 emissions – those in our supply chains – account for the most substantial part of our footprint. We have identified relevant emission categories over the past year, including, for example, the purchase of primary chemical products for medicines at Fresenius Kabi and the procurement of medicines at Helios and Quirónsalud. Going forward, we will concentrate on setting a company-wide target for reducing these types of emissions.
In addition, we will continue to focus on issues such as water consumption. Our aim is to reduce our process water consumption at sites in areas of water stress by 20 percent by 2030. We will also ramp up our sustainability communication activities and stakeholder engagement.
You mention stakeholders. Who are you referring to and what does engagement mean in this regard?
Sarah Tix: We are involved in various organizations and professional bodies. What’s more, we engage in direct dialogue with our employees, patients, and investors. Last year, we set up an external Sustainability Advisory Board to assist us as we continue to develop our activities. Its members possess real expertise in the areas of relevance to us – covering matters such as sustainability in healthcare, environmental protection, human rights, and sustainable human resource management. In the first year of working with the board, we received valuable input – on our strategic approach, for example. We value the open and constructive dialogue and the commitment of all members who support us both as a body and as individuals.
Fresenius, via its operating company Fresenius Kabi, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to its Adaptive Nomogram, an alternate algorithm that will be available in the Aurora Xi Plasmapheresis System.
The Adaptive Nomogram enables an average 11.5% increase in plasma collection per donation while maintaining safe and effective operation. This enhanced capability will allow plasma centers to improve collection efficiency. Plasma-derived therapies are essential for treating a wide range of conditions, including immune deficiencies, bleeding disorders, and neurological diseases. By increasing plasma collection efficiency, Fresenius Kabi reinforces its commitment to improving access to these critical therapies. The clearance received for the Adaptive Nomogram is another milestone in line with #FutureFresenius.
Fresenius, via its operating company Fresenius Kabi, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to its Adaptive Nomogram, an alternate algorithm that will be available in the Aurora Xi Plasmapheresis System.
The Adaptive Nomogram enables an average 11.6% increase in plasma collection per donation while maintaining safe and effective operation. This enhanced capability will allow plasma centers to improve collection efficiency. Plasma-derived therapies are essential for treating a wide range of conditions, including immune deficiencies, bleeding disorders, and neurological diseases. By increasing plasma collection efficiency, Fresenius Kabi reinforces its commitment to improving access to these critical therapies. The clearance received for the Adaptive Nomogram is another milestone in line with #FutureFresenius.
Fresenius has signed a new five-year global contract with Microsoft focused on collaboration and IT security for all Fresenius employees. Starting in June 2025, the contract will encompass tools such as Microsoft Defender, Microsoft 365, SharePoint, OneDrive, and Microsoft Power BI, combining the license demands of all Fresenius segments under one agreement. The objective is to streamline and simplify daily office operations for employees while enhancing security capabilities.
“This contract represents another milestone and is a substantial improvement to our IT foundation. We are moving to a comprehensive and state-of-the-art ecosystem across all segments,” says Ingo Elfering, Chief Information Officer of the Fresenius Group.
The collaboration between Fresenius and Microsoft, expanding since 2022, focuses on cloud computing, security features, collaboration features and AI enablement. It has facilitated successful large-scale cloud migrations at Fresenius and established the groundwork for further innovation and change initiatives.
“Our Microsoft technology helps Fresenius to focus more on their customers and patients and less on IT management. Security and data protection are our top priorities in its development. Microsoft plays a central role in the digital ecosystem, and this comes with a critical responsibility to earn and maintain trust, especially in healthcare”, explains Michael Sahnau, Director Health & Life Science at Microsoft Germany.
Looking ahead, the collaboration will enhance the capabilities especially of Fresenius’ Helios Group with advanced Artificial Intelligence adoption and new cloud technologies. It will also expand across all of Fresenius cloud migration strategy and a modern, harmonized, and cost-efficient IT framework.
Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE) is a global healthcare company headquartered in Bad Homburg v. d. Höhe, Germany. In the 2023 fiscal year, Fresenius generated €22.3 billion in annual revenue. Fresenius offers solutions to the social challenges posed by a growing and ageing population and the resulting need for affordable, high-quality healthcare. Fresenius currently counts over 175,000 employees. The Fresenius Group comprises the operating companies Fresenius Kabi and Fresenius Helios as well as the investment company Fresenius Medical Care. With 140 hospitals and countless outpatient facilities, Fresenius Helios is the leading private hospital operator in Germany and Spain, treating around 26 million patients every year. Fresenius Kabi’s product portfolio includes a range of highly complex biopharmaceuticals, clinical nutrition, medical technology, and generic intravenous drugs. Fresenius was established in 1912 by the Frankfurt pharmacist Dr. Eduard Fresenius. After his death, Else Kröner took over management of the company in 1952. She laid the foundations for a global enterprise that today pursues the goal of improving people’s health. The largest shareholder is the non-profit Else Kröner-Fresenius Foundation, which is dedicated to advancing medical research and supporting humanitarian projects.